Benitec Biopharma Ltd (BNTC)

[georgejjl]

Hoyland was completely wrong in this case

Because a majority of cells are not transduced, initial cohorts are for safety only, no efficacy expected
Transduction levels roughly consistent with pre-clinical studies:

QPCR analysis:
• Subject 1 cohort 1 (4e10 vg/kg): 0.02 copies TT-034 per cell (average)
• Subject 2 cohort 1 (4e10 vg/kg): 0.01 copies TT-034 per cell (average)
• Subject 1 cohort 2 (1.25e11 vg/kg): 0.48 copies TT-034 per cell (average)

If consistent with pre-clinical studies, cohort 3 may have significantly higher percentage of DNA transduction

The numbers transducer in the first two cohorts were right in order with the numbers induced in the preclinical studies. Therefore, it can be expected that there will be a significant reduction of the hepatitis C viral load in the third cohort.

Good luck and GOD bless,

George